Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare to Supply CytoGenix With DNA Production Reagents Exclusively for Compound Manufacturing

This update serves to clarify the fact that GE has licensed its production reagents exclusively to CytoGenix for the company to use in compound manufacturing.


NEW YORK, March 23 (GenomeWeb News) - GE Healthcare will exclusively provide its DNA production reagents to CytoGenix where the intended application is the manufacture of therapeutic compounds, CytoGenix said today in a statement.


A CytoGenix spokesperson said other labs or companies can license the reagents for purposes other than compound manufacturing.


The companies did not disclose financial terms of the agreement.


Houston, Tex.-based CytoGenix manufactures DNA-based vaccines and therapeutics for infectious diseases, inflammatory disorders, and cancer.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.